An anti-ER “Riptac” enters phase 1.
ApexOnco Front Page
Recent articles
Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
Keymed’s AstraZeneca-partnered anti-Claudin18.2 ADC looks better than Astellas’s zolbetuximab – albeit on an extremely unreliable metric.
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
But the groups have yet to see any responses with AU-007 and XTX202 respectively.
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.